ADC THERAPEUTICS AMERICA, INC.

ADC Therapeutics America, Inc. specializes in the development and manufacturing of antibody drug conjugates (ADCs), with core capabilities centered on pharmaceutical preparation manufacturing, stability testing, and Drug Master File (DMF) maintenance. The company provides end-to-end support for biopharmaceutical candidates, including analytical characterization, accelerated stability studies, and regulatory documentation required for FDA submissions. Their technical expertise lies in the formulation, processing, and lifecycle management of complex biologics, particularly in maintaining compliance with cGMP standards and ensuring product integrity through rigorous quality control protocols. A key differentiator is their focused execution in ADC-specific regulatory pathways, demonstrating proficiency in navigating the intricate requirements for novel therapeutics in oncology and targeted treatment spaces. The contractor has delivered services to the Department of Veterans Affairs and the Program Support Center’s Acquisition Management Services, primarily supporting pharmaceutical development and regulatory compliance initiatives. Their engagement with these agencies reflects a pattern of non-competitive, mission-critical contracts focused on sustaining the regulatory readiness of advanced therapeutics for veteran healthcare programs. The primary NAICS code 325412 reflects active involvement in the manufacturing of pharmaceutical preparations, specifically biologics and targeted therapies. This positions the company within the niche segment of oncology-focused biopharmaceutical development, where precision medicine and complex conjugate technologies are central. Their market presence is defined by technical specialization rather than broad-scale production. ADC Therapeutics America, Inc. is structured as a 2L entity headquartered in New Providence, New Jersey. While no federal certifications are listed, their operational focus on cGMP-compliant manufacturing and regulatory documentation aligns with stringent federal biopharma standards. The company maintains a targeted, expertise-driven footprint in the government biopharmaceutical market, serving specialized needs within federal health agencies.